Sign in

You're signed outSign in or to get full access.

HM

HTG MOLECULAR DIAGNOSTICS, INC (HTGMQ)·Q4 2022 Earnings Summary

Executive Summary

  • Q4 2022 revenue inflected sharply to roughly $2.44M, up ~95% QoQ versus Q3 ($1.25M), consistent with management’s “nearly 95%” commentary; full-year 2022 revenue was $6.37M .
  • Cash and cash equivalents were approximately $12.2M at year-end, supported by December financing activity; management emphasized a leaner profiling business and tighter spend to support drug discovery milestones .
  • HTP adoption accelerated: FY22 HTP revenue was ~$1.8M (47% of product revenue), and the company disclosed ~$2.7M HTP revenue representing 42% of total FY22 revenue, reinforcing mix shift toward transcriptome panel demand .
  • No quantitative Q4 guidance or EPS disclosed in the Q4 press release and no Q4 earnings call transcript available; consensus estimates from S&P Global were unavailable for HTGMQ due to mapping limitations. This limits beat/miss analysis for EPS and revenue vs. Street.

What Went Well and What Went Wrong

What Went Well

  • Strong Q4 revenue inflection: “revenue grow by nearly 95% from the third quarter to the fourth quarter of 2022,” driven by repeat kit/service orders and new customers .
  • HTP adoption momentum: FY22 HTP consumables revenue grew $1.3M YoY to ~$1.8M, representing 47% of product revenue, signaling expanding usage of the transcriptome panel .
  • Balance sheet actions and liquidity: Preliminary cash and equivalents of ~$12.2M at 12/31/22; financing activities net inflows in December supported liquidity while management “focused on right-sizing” profiling operations .

What Went Wrong

  • Full-year revenue declined 29% YoY to $6.37M amid slower-than-anticipated recovery in oncology and profiling markets; management acknowledged profiling revenue “did not show the level of recovery anticipated in 2022” .
  • Persistent operating losses: FY22 operating loss was $(20.83)M; nine-month 2022 operating loss was $(16.28)M, implying a Q4 operating loss of roughly $(4.55)M .
  • Gross margin pressure in Q4: while Q3 gross margin recovered to ~46%, Q4 gross margin dipped to ~17% (derived from FY vs. nine-months), suggesting mix and scale headwinds despite revenue growth .

Financial Results

Quarterly P&L Metrics

MetricQ2 2022Q3 2022Q4 2022
Revenue ($USD Millions)$1.492 $1.251 ~$2.439 (FY $6.366 − 9M $3.927)
QoQ Growth (%)—−16.1% (from $1.492 to $1.251) +94.9% (from $1.251 to ~$2.439), “nearly 95%”
YoY Growth (%)−28.1% (vs. $2.074 in Q2’21) −50.4% (vs. $2.520 in Q3’21) N/A (Q4’21 quarterly not disclosed)
Net Loss ($USD Millions)$(5.888) $(4.516) ~$(4.693) (FY $(21.594) − 9M $(16.902))
EPS ($USD)$(0.54) $(0.41) N/A (not disclosed in Q4 PR)
Gross Margin (%)~32.0% (Rev $1.492 − CoGS $1.014) ~46.4% (Rev $1.251 − CoGS $0.671) ~16.7% (Rev ~$2.439 − CoGS ~$2.032)
EBIT ($USD Millions)$(5.677) $(4.348) ~$(4.551) (FY $(20.830) − 9M $(16.279))
EBIT Margin (%)−381% −348% −187%
Street Revenue Consensus ($USD Millions)N/A (S&P Global mapping unavailable)N/A (S&P Global mapping unavailable)N/A (S&P Global mapping unavailable)

Notes: Q4 2022 revenue and costs are derived from FY minus nine-months actuals; consensus estimates were unavailable due to S&P Global mapping limitations for HTGMQ.

FY 2022 Revenue Breakdown

CategoryFY 2022 ($USD)FY 2021 ($USD)
Instrument$609,627 $1,385,665
Consumables$3,140,420 $3,786,923
Total Product Revenue$3,750,047 $5,172,588
Custom RUO Assay Design$20,000 $48,350
RUO Sample Processing$2,596,173 $3,685,890
Total Product-Related Services$2,616,173 $3,734,240
Total Product + Services$6,366,220 $8,906,828
HTP Consumables (subset)~$1,800,000 ~$1,300,000
HTP Share of Total Revenue~$2.7M (42%) N/A

KPIs and Operating Metrics

KPIQ2 2022Q3 2022Q4 2022
Active CustomersN/A77 N/A
Active Pharma Programs50 57 N/A
Instruments Producing RevenueN/A50 N/A
New Customers/Programs+11 new customers in Q2 21 new customers YTD; 15 new pharma-sponsored clinical trials YTD N/A
Cash & Equivalents$14.1M (as of 6/30/22) $6.5M (as of 9/30/22) ~$12.2M (as of 12/31/22)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueQ4 2022 / FY 2022None disclosedPreliminary FY22 revenue ~$6.4M (press release) New preliminary disclosure
Cash & Equivalents12/31/2022None disclosed~$12.2M New preliminary disclosure
OpEx/Margins/EPSQ4/FY 2022None disclosedNot provided in Q4 PRMaintained “no guidance”
Drug Discovery PartneringFY 2022 exitBegin partnering conversations by YE 2022 Reiterated strategic focus; no numeric guidance Maintained qualitative
Note: No quantitative revenue, margin, OpEx, or EPS guidance ranges were provided for Q4; disclosures were preliminary and qualitative.

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2022)Previous Mentions (Q3 2022)Current Period (Q4 2022)Trend
Drug discovery platform progressAchieved H1 milestones; library designed for first target; preclinical characterization next; plan to start partnering by YE’22 Continued algorithm refinement; internal data for ML; internal cell culture capability; early efficacy data; partnering by YE’22 with second target in 2023 Focus on preserving drug discovery milestones while right-sizing profiling; no specific Q4 milestone update in PR Strategic; steady build; prioritization intact
Profiling market recoveryOncology recovery slower than hoped; growing HTP demand; added 11 new customers 77 active customers; 57 active pharma programs; optimism in pipeline; HTP became biggest selling product Q4 revenue up ~95% QoQ; HTP $2.7M in FY22 (42% total revenue) Improving demand; revenue inflection
Cash/liquidity and spend disciplineAmended SVB facility; prepaid $2.5M; end Q2 cash + ST investments $14.1M End Q3 cash + ST investments $6.5M; cost control; right-sizing ~$12.2M cash at YE; “increasing efficiencies and minimizing spend” Strengthened YE liquidity
Customer engagement & disease areasBroader use beyond oncology (e.g., derm); more access to customers post-COVID New pharma programs and OEM conversations; installed base yielding revenue Q4 growth included reorders and new customers Positive engagement
Regulatory/legalN/AN/AForward-looking risk reminders; going concern flagged in 10-K Risk context persists

Management Commentary

  • “We are encouraged to see revenue grow by nearly 95% from the third quarter to the fourth quarter of 2022... orders from customers who have previously adopted our technology... as well as orders from new customers.” — John Lubniewski, CEO
  • “Considering recent revenue performance in our profiling business, we are focused on right-sizing this business, increasing efficiencies and minimizing spend without jeopardizing our ability to generate higher levels of profiling revenue or impacting our drug discovery milestones.” — CEO
  • “HTP consumables revenue represented 47% of our product revenue for the year ended December 31, 2022... reflecting expanding adoption.” — FY22 discussion
  • “We have achieved our third quarter 2022 milestones and remain on track to begin partnering conversations for our first target and indication by the end of 2022.” — CEO (Q3 PR)

Q&A Highlights

  • Publication pipeline and HTP adoption: Management expects “between 3 and 5 additional papers” following the first peer-reviewed HTP article, with growing shift to whole-transcriptome products .
  • Expansion beyond oncology: Increased customer access and exploration in new disease areas (e.g., dermatology) with larger cohorts; positive dialogues for Q3/Q4 .
    Note: No Q4 earnings call transcript was found; Q2 2022 highlights are provided for context.

Estimates Context

  • Wall Street consensus estimates from S&P Global for HTGMQ were unavailable due to missing company mapping in SPGI/Capital IQ systems. As a result, we cannot assess Q4 revenue or EPS vs. estimates or determine beats/misses.
  • We searched for estimates via S&P Global tools, but mapping errors prevented retrieval.

Key Takeaways for Investors

  • Q4 revenue inflection (~95% QoQ) suggests demand recovery and HTP-led mix shift; the sequential strength is a potential near-term trading catalyst if sustained .
  • Margin pressure in Q4 despite revenue growth indicates scale/mix sensitivity; watch gross and EBIT margins as volume ramps .
  • HTP adoption is central to the thesis: ~$1.8M FY22 HTP consumables and ~$2.7M total HTP revenue (42% of total) support continued product-led growth .
  • Liquidity improved by year-end with ~$12.2M in cash; cost controls and “right-sizing” profiling reduce burn while preserving drug discovery milestones .
  • Lack of Q4 EPS disclosure and unavailable consensus estimates limit immediate beat/miss optics; focus near term on revenue trajectory, bookings, and pipeline conversions.
  • Medium-term, drug discovery milestones/partnering outcomes could be catalysts; management maintained emphasis on partnering readiness and platform differentiation .
  • Monitor instrument placements, OEM opportunities, and broader disease-area adoption to gauge durable revenue recovery beyond oncology .

Sources

  • Q4 2022 preliminary results (8-K, Item 2.02; Exhibit 99.1 press release, Jan 6, 2023)
  • Q3 2022 results (8-K press release, Nov 10, 2022), including financial tables and KPIs
  • Q2 2022 results (8-K press release, Aug 11, 2022) and earnings call transcript
  • FY 2022 10-K, revenue breakdowns and financial statements
  • Additional press release coverage (GlobeNewswire), preliminary FY22 details and Q4 commentary